Navigation

Atopic dermatitis (eczema) - pimecrolimus and tacrolimus

Pimecrolimus & tacrolimus for atopic dermatitis (eczema)

Status: History
Expected date of issue: August 2004
Process: MTA
Topic area:
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Zoe Charles
Communications manager: Phil Ranson
Project manager: Sarah Cumbers
Assessment Group / Evidence Review Group: Peninsula Technology Assessment Group (PenTAG), University of Exeter
Top


 

Provisional schedule

Information meeting with consultees: 21 August 2003
Closing date for invited submissions / evidence submission: 16 October 2003
Final scope published: June 2003
1st appraisal committee meeting: 09 March 2004
2nd appraisal committee meeting: 13 May 2004
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Fujisawa Limited
  • Novartis

Patient / Carer Groups

  • British Association of Dermatologists
  • National Association of Primary Care
  • National Eczema Society
  • Primary Care Dermatology Society
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Physicians
  • Royal Pharmaceutical Society
  • Skin Care Campaign

Professional Groups

  • None

Others

  • Department of Health
  • Kensington and Chelsea Primary Care Trust
  • Welsh Assembly Government

General

  • British National Formulary
  • NHS Confederation
  • NHS Purchasing and Supplies Agency
  • NHS Quality Improvement Scotland

Comparator Manufacturers

  • None

Assessment Team

  • None

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Research Groups

  • Centre of Evidence-based Dermatology, University of Nottingham
  • Cochrane Skin Group
  • Skin Treatment & Research Trust

Top


 

Project history

Date Update
7 April 2004 List of Invited Consultees and Commentators added.
7 December 2005 This appraisal is now published. See published appraisal
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.